The renin inhibitor aliskiren showed no benefit when added to ACE-inhibitor/ARB treatment in diabetic patients at high cardiovascular and renal risk and increased the risk of stroke and hyperkalemia.
via The Heart
via The Heart
The India Cardiology 2.0 Medical Social Media Network
No comments:
Post a Comment